Drug Type Small molecule drug |
Synonyms HP515 |
Target |
Action inhibitors |
Mechanism THR-β inhibitors(Thyroid hormone receptor beta inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic dysfunction-associated steatotic liver disease | Phase 2 | China | 10 Sep 2025 | |
Nonalcoholic Steatohepatitis | Phase 1 | China | 27 Dec 2024 | |
Diabetes Mellitus | Preclinical | China | 01 Jun 2025 | |
Obesity | Preclinical | China | 01 Jun 2025 |